Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) has received approval from the National Medical Products Administration for its injectable Cefoperazone Sodium, indicating a successful evaluation of the drug's quality and efficacy consistency as a generic medication [1]. Group 1 - The company’s subsidiary, Harbin Pharmaceutical Group Pharmaceutical Factory, is the entity that received the approval for the injectable Cefoperazone Sodium [1]. - The approved formulations include 1.0g and 0.5g dosages, with specific notification numbers for each [1]. - Injectable Cefoperazone Sodium is indicated for various infections caused by sensitive bacteria, including lower respiratory tract infections, urogenital infections, gynecological infections, bacteremia/sepsis, skin and soft tissue infections, abdominal infections, bone and joint infections, and central nervous system infections [1].

格隆汇2月10日｜英国制药巨头阿斯利康公布2025年业绩，全年总营收达到587.39亿美元，按固定汇率 计同比增长8%，主要得益于肿瘤、心血管和罕见病业务板块的增长；其中，产品销售额为555.73亿美 元，同比增长9%；核心每股收益为9.16美元，同比增长11%。就2025年第四季度而言，总营收为155.03 亿美元，同比增长2%；核心每股收益为2.12美元，同比下滑2%。 展望2026年，阿斯利康预计总营收将实现中高个位数百分比的增长，核心每股收益将实现低两位数百分 比的增长。 阿斯利康首席执行官Pascal Soriot表示："2025年，公司在各个治疗领域都取得了强劲的商业表现，研发 管线进展顺利。公司公布了16项积极的三期临床试验结果，目前拥有16款重磅药物。展望2026年，公司 将继续保持增长势头，期待今年公布超过20项三期临床试验的结果。"公司宣布派发第二次中期股息， 每股2.17美元；2025年总股息增长3%至每股3.2美元。 ...

医药赛道方面，2025年多项关键性的创新药BD为未来复星创新药的可持续性增长，打下了坚实的基 础。其中，复星医药控股子公司药友制药与辉瑞签订全球独家许可协议，授予辉瑞口服小分子GLP-1药 物YP05002全球范围内独家开发、生产及商业化权利，协议包含首付款、里程碑付款及销售分层特许权 使用费，潜在总金额超20亿美元；复星医药控股子公司复星医药产业与生物技术公司Clavis Bio达成战 略合作，双方将基于由Clavis Bio提名的前沿靶点共同开发创新疗法，根据协议，复星医药将可获得至 多72.5亿美元付款。 2026年开年以来，复星在旅文、医药、保险等核心赛道表现亮眼。公开信息显示，复星旗下ClubMed国 内5家精致"一价全包"度假村入境营业额较去年同期实现翻三倍增长，旗下生物医药研发平台复宏汉霖 宣布与卫材株式会社就抗PD-1单抗汉斯状在日本达成独家商业化及共同独家开发与生产许可协议，潜 在总金额超3亿美元。 新春旅游需求的承接及创新药的持续商业化落地等，延续了复星2025年核心赛道稳中有升的发展态势。 纵观复星过去一年的发展和今年的开年势头，"瘦身健体"的战略推进依旧坚定：退出一些非核心项目的 同时 ...

消息面上，2月7日，亿腾嘉和宣布ANGPTL3siRNA新药EDP167完成二期临床试验首例受试者给药。 EDP167此次开展的是一项针对纯合子家族性高胆固醇血症(HoFH)成人患者的多中心、剂量探索、开放 标签的试验，主要终点为给药24周后LDL-C水平相较基线的变化，预计于2026年Q4完成主要终点的评 估。 值得注意的是，12月30日，亿腾医药以反向收购方式完成与嘉和生物的换股合并和上市。此次反向收购 的达成，标志着亿腾嘉和的正式成立，并在战略整合与发展上迈入全新阶段。嘉和生物-B中文股份简称 则由"嘉和生物"更改为"亿腾嘉和"，自2026年2月6日起上午九时正起生效。 亿腾嘉和(06998)尾盘涨近9%，截至发稿，涨6.88%，报2.95港元，成交额350.91万港元。 ...

Group 1 - The core point of the article is that Eton Pharma (06998) experienced a nearly 9% increase in stock price, currently trading at 2.95 HKD, with a trading volume of 3.5091 million HKD following the announcement of the completion of the first dosing in a Phase II clinical trial for the new drug EDP167 [1] - EDP167 is being tested in a multicenter, dose-exploration, open-label trial targeting adult patients with homozygous familial hypercholesterolemia (HoFH), with the primary endpoint being the change in LDL-C levels from baseline after 24 weeks of treatment, expected to complete the primary endpoint assessment by Q4 2026 [1] - On December 30, Eton Pharma completed a reverse acquisition with Jiahe Biotech, marking the official establishment of Eton Pharma and entering a new phase in strategic integration and development, with the Chinese stock name changing from "Jiahe Biotech" to "Eton Pharma" effective February 6, 2026 [1]

Core Viewpoint - The company Xuantai Pharmaceutical (688247.SH) has announced its participation in the national centralized procurement for the continuation of products whose agreements have expired, with its product ursodeoxycholic acid capsules expected to be selected in this procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the national centralized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Market Impact - The procurement process prioritizes the use of selected drugs by medical institutions, ensuring the completion of the agreed purchase volume [1] - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products, increase market share, and enhance brand influence [1] - This development is expected to have a positive impact on the company's future operating performance [1]

Core Viewpoint - XuanTai Pharmaceutical (688247.SH) has participated in the national centralized procurement for the continuation of products from the first to eighth batches, with its product, ursodeoxycholic acid capsules, being proposed for selection in the continuation procurement process [1] Group 1: Procurement Participation - The company has submitted an application for the continuation procurement of products whose agreements have expired, as announced by the continuation procurement office on February 10, 2026 [1] - The proposed selection of the company's product indicates a potential for increased sales and market share [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will likely enhance the sales scale and brand influence, positively affecting future operational performance [1]

Core Viewpoint - The company announced that its subsidiary, Harbin Pharmaceutical Group, received approval from the National Medical Products Administration for the injectable Cefotaxime Sodium (1.0g, 0.5g), which has passed the consistency evaluation for generic drugs [1] Group 1: Product Approval and Market Impact - The approved drug is indicated for various infections, which may enhance the company's product portfolio [1] - The projected domestic sales for 2024 are estimated at 1.55 billion yuan, with 889 million yuan expected in the first three quarters of 2025 [1] - The company has invested approximately 8.1573 million yuan in research and development for this product [1] Group 2: Competitive Position and Future Prospects - Passing the consistency evaluation is expected to help expand the drug's market share and improve competitiveness [1] - The company acknowledges that drug sales are influenced by multiple factors, indicating potential uncertainties in future performance [1]

步长制药公告称，2026年2月10日，公司控股股东步长（香港）办理股份解除质押及再质押手续。步长 （香港）本次解质893万股，占其所持股份1.82%，占总股本0.85%；同日再质押893万股，占其所持股 份1.82%，占总股本0.85%，质押融资用于经营所需。本次操作后，步长（香港）累计质押1.09亿股，占 其所持股份22.11%，占总股本10.29%。步长（香港）及其一致行动人累计质押1.09亿股，占所持股份 18.14%，占总股本10.29%。本次质押不会致实控权变更，不影响公司经营。 ...

Core Viewpoint - Xuantai Pharmaceutical (688247.SH) has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, with its product, ursodeoxycholic acid capsules, being proposed for selection in this procurement process [1] Group 1: Procurement Participation - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The procurement office released the proposed selection results on February 10, 2026, indicating that the company's product is likely to be selected [1] Group 2: Impact on Business - If the company signs procurement contracts and implements them, it will help expand the sales scale of its products [1] - The selection is expected to increase the company's market share and enhance brand influence, positively impacting future operating performance [1]